
Alphabet Reports Results… And Pharma Stocks Diverge In Weight Loss Drug Race 2/4/26
CNBC's "Fast Money"
00:00
Lilly Soars While Novo Slides
Jared Holtz explains divergent earnings: Lilly's strong weight‑loss sales versus Novo's cautious guidance and pricing headwinds.
Play episode from 30:26
Transcript


